Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$13.94 0.20 (1.46%)
2/9/2010 4:01 PM

Biovail Corp (USA) (BVF)

CAPS Rating:
***

A specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. Its main therapeutic areas are central nervous system disorders, pain management and cardiovascular disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BVF

Add Stock to Watchlist

What the Community Thinks

Total Members

458 Outperforms
35 Underperforms
 

All-Stars

131 Outperforms
13 Underperforms
 

Wall Street

9 Outperforms
1 Underperforms
 

Members bullish on BVF are also bullish on:

Members bearish on BVF are also bearish on:

Ticker Tags

Defensive (1457), Healthcare (711), Small Cap (1645), International Stock (684), Canada (69), Pharmaceuticals (149)
Suggest a tag

Biovail Corp (USA) At A Glance

Current Price: $13.94
Last Trade Time: 2/9/2010 4:01 PM
Open: $0.00
Previous Close: $13.74
Daily Range: $13.74 - $14.04
52-Week Range: $9.26 - $16.14
Volume: 748,537
Market Cap: $2.21B
P/E Ratio: 9.81
Compare Our Special Broker Offers!

Stock Trends

BVF VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Biovail Corp (USA) (BVF)

Avatar Grinnell4Eva (83.11) Submitted: 5/30/08 10:27 AM

Wellbutrin generics should continue to come under pressure from their poor efficacy vis-a-vis the brand name product. Huge buybacks on the horizon. Refocused management has put past scandals behind them and looks to pour cash into R & D pipeline stocked with potential market-leading products.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

3

Biovail Corp (USA) (BVF)

Avatar Civildriver (< 20) Submitted: 1/03/08 4:39 PM

BVF stock is a big money losser.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 75 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (BVF)

Avatar fhashtpari (< 20) Submitted: 2/01/10 12:17 PM : Outperform Start Price: $14.93 BVF Score: -5.46

BVF's internal infighting with EX CEO is over and the company is executing to their strategic plan. They lowered their dividend payout to maintain cash requirements for their strategic business expansion. I like what the management team has accomplished over the past year in spite of all commotions created by EX CEO.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BVF)

Avatar BigBeau89 (44.90) Submitted: 12/26/09 7:43 PM : Outperform Start Price: $14.01 BVF Score: 4.53

The nervous system, cardiovascular disease, and pain management all are areas of many disorders and problems. The drugs this company makes would be helpful to people, and I don't think it would matter what health care comes our way, because these drugs are needed.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BVF)

Avatar Bogey02 (36.19) Submitted: 12/24/09 1:57 PM : Outperform Start Price: $14.01 BVF Score: 4.53

Intermediate horizon looks good with several candidates to replace patent expiring drugs. Generics are going to be more and more attractive in a fiscally constrained environment. Safe pick given book value and although dividend was cut recently, room to add on there moving forward.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BVF)

Avatar lonewulf47638 (63.75) Submitted: 12/21/09 12:32 PM : Outperform Start Price: $14.01 BVF Score: 3.36

drugs will rise next year

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BVF)

Avatar spreadsheetV1 (94.05) Submitted: 11/23/09 1:27 AM : Outperform Start Price: $14.22 BVF Score: 1.19

This met a high level screen to indicate a buy and strong outperform against its peers (other tickers in its industry). My 1st version of this spreadsheet devles deep into the company's balnace sheet and recent income statements, combined with other relevant price data for the company including insider/institutional holdings, short interest, debt levels, etc.
Testing capabilities of this 1st version of my automated, valuation spreadhseet matched with my personal criteria and see how it holds up.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 75 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackTWeisel < 20 12/17/09 Outperform NS $13.75+1.38%-3.16%+4.54
TrackJPMorgan 84.76 09/26/09 Outperform NS $13.89+0.35%+2.33%-1.98
TrackCreditSuiss 93.62 09/15/09 Outperform NS $13.09+6.52%+3.71%+2.81
TrackDeutscheSec 89.68 05/08/09 Outperform NS $10.25+36.02%+17.72%+18.30
TrackCanaccord 86.15 09/17/08 Outperform NS $8.79+58.51%-6.56%+65.07
TrackDreman 93.64 09/30/07 Outperform NS $13.99-0.35%-26.38%+26.03 Toggle the visibility of 60-Second Pitch and replies
TrackBrandes < 20 09/30/07 Outperform NS $13.99-0.35%-26.38%+26.03 Toggle the visibility of 60-Second Pitch and replies
TrackJimCramer < 20 05/11/07 Underperform 3W $19.18-27.31%-24.86%+2.44
TrackBroadpoint.AmTech 76.97 12/07/06 Outperform NS $16.17-13.79%-19.89%+6.11
TrackRBCCapMkts 86.33 09/26/06 Outperform NS $11.44+21.90%-14.10%+36.00

Results 1 - 10 of 10  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 875ms